The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget
Author(s)
Panagiotis Paterakis, MSc, PharmD, PhD, Elisavet Komnineli, MBA, MSc, PharmD, Anastasia Seimeni, MSc, PharmD, PANAGIOTA LITSA, MSc, PharmD, Nandia Gogozotou, MBA, MSc, PharmD, PhD.
Drug Price Negotiation Committee, Greek Ministry of Health, Athens, Greece.
Drug Price Negotiation Committee, Greek Ministry of Health, Athens, Greece.
OBJECTIVES: In Greece, since 2012 a ceiling has been imposed on outpatient pharmaceutical expenditure, aligning with the average level of European Union countries. For the period 2020-2024, this ceiling increased from €2.088 billion to €2.187 billion. Expenditure exceeding this limit is covered through the clawback mechanism, for which a gradual reduction has been targeted [Recovery and Resilience Facility (RRF) goals] since 2022. To support this objective, the Drug Price Negotiation Committee (DPNC) was activated by the Ministry of Health. According to its founding law, the DPNC establishes agreements of closed budgets or confidential discounts with Drugs’ Marketing Authorization Holders. This study examines the impact of the DPNC on clawback containing.
METHODS: We utilized data from the databases of the DPNC and the National Organization for Healthcare Services Provision (EOPYY). We collected, documented, and analyzed sales performance data for retail and high-cost medicines, and financial values of the DPNC’s agreements, to assess their contribution to reducing the clawback burden.
RESULTS: Between 2020 and 2024, 1,046 agreements were signed, most of them in closed budget. Outpatient pharmaceutical expenditure increased from €3.7 billion in 2020 to €3.9 billion in 2021, €4.2 billion in 2022, €4.6 billion in 2023, and €4.9 billion in 2024. At the same time, additional negotiated discounts, which exceeded the legally provided discounts, amounted to €78 million in 2020, €203 million in 2021, €427 million in 2022, €550 million in 2023, and €688 million in 2024, thus leading to a significant slowdown in the growth rate of clawback.
CONCLUSIONS: The DPNC has significantly contributed to controlling the growth trajectory of clawback payments in Greece, by achieving specifically in 2024, €688 million additional to the rebates negotiated discounts, which results in a slight €97 million rise in clawback versus 2023.
METHODS: We utilized data from the databases of the DPNC and the National Organization for Healthcare Services Provision (EOPYY). We collected, documented, and analyzed sales performance data for retail and high-cost medicines, and financial values of the DPNC’s agreements, to assess their contribution to reducing the clawback burden.
RESULTS: Between 2020 and 2024, 1,046 agreements were signed, most of them in closed budget. Outpatient pharmaceutical expenditure increased from €3.7 billion in 2020 to €3.9 billion in 2021, €4.2 billion in 2022, €4.6 billion in 2023, and €4.9 billion in 2024. At the same time, additional negotiated discounts, which exceeded the legally provided discounts, amounted to €78 million in 2020, €203 million in 2021, €427 million in 2022, €550 million in 2023, and €688 million in 2024, thus leading to a significant slowdown in the growth rate of clawback.
CONCLUSIONS: The DPNC has significantly contributed to controlling the growth trajectory of clawback payments in Greece, by achieving specifically in 2024, €688 million additional to the rebates negotiated discounts, which results in a slight €97 million rise in clawback versus 2023.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HTA316
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas